PODDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INSULET CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$141.96+0.86 (+0.61%)
Close on Oct 19, 2026
- Market cap
- $9.85B
- P/E (TTM)
- 26.5
- Dividend yield
- –
INSULET CORP revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Omnipod products | $3.04B | $2.88B | $2.67B | $2.48B | $2.31B | $2.15B | $2.03B | $1.95B | $1.84B | $1.74B | $1.66B | $1.53B | 99.4% | +31.3% |
| U.S. | $2.12B | $2.03B | $1.92B | $1.80B | $1.69B | $1.59B | $1.51B | $1.46B | $1.39B | $1.31B | $1.25B | $1.13B | 69.6% | +25.4% |
| International | $910.90M | $844.90M | $754.30M | $682.20M | $618.00M | $560.40M | $523.40M | $487.80M | $451.30M | $426.80M | $410.10M | $393.90M | 29.8% | +47.4% |
| Drug Delivery | $18.10M | $22.50M | $34.10M | $44.00M | $47.20M | $45.10M | $38.90M | $35.90M | $36.30M | $44.20M | $36.00M | $30.50M | 0.6% | -61.7% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.14B | $2.06B | $1.95B | $1.84B | $1.74B | $1.64B | $1.55B | – | – | – | – | – | 70.2% | +23.1% |
| International | $910.90M | $844.90M | $754.30M | $682.20M | $618.00M | $560.40M | $523.40M | – | – | – | – | – | 29.8% | +47.4% |
From the segment and revenue-disaggregation notes of Insulet's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.